瑞舒伐他汀联合盐酸羟考酮缓释片治疗晚期非小细胞肺癌患者癌痛的效果

Effect of Rosuvastatin combined with oxycodone hydrochloride sustained-release tablets on cancer pain in patients with advanced non-small cell lung cancer

目的探讨瑞舒伐他汀联合盐酸羟考酮缓释片对晚期非小细胞肺癌患者的癌痛作用。方法选择我院2017年8月~2018年3月期间收治的84例晚期非小细胞肺癌患者作为本次研究病例,按照计算机表法对其进行分组,各42例,对照组行盐酸羟考酮缓释片治疗,研究组加用瑞舒伐他汀治疗,比较两组的白介素-6、肿瘤坏死因子α水平以及治疗效果。结果治疗后,研究组IL-6、TNF-α水平显著低于对照组,且研究组治疗后指标水平低于治疗前(P<0.05),研究组爆发痛次数与NRS评分明显少于对照组(P<0.05),盐酸羟考酮缓释片的有效剂量少于对照组(P<0.05),研究组不良反应发生率低于对照组(P<0.05)。结论瑞舒伐他汀联合盐酸羟考酮缓释片对晚期非小细胞肺癌患者癌痛有明显的增效作用,能够有效降低不良反应发生率。

Objective To explore the effect of rosuvastatin combined with oxycodone hydrochloride sustained-release tablets on cancer pain in patients with advanced non-small cell lung cancer. Methods A total of 84 patients with advanced non-small cell lung cancer admitted to our hospital from August 2017 to March 2018 were selected as the study cases. According to the computerized method, the patients were divided into two groups, 42 cases in each group. The control group was treated with oxycodone hydrochloride sustained-release tablets, and the study group was additionally treated with rosuvastatin. The levels of interleukin-6 and tumor necrosis factor α and the therapeutic effects were compared between the two groups. Results After treatment, the levels of IL-6 and TNF-α in the study group were significantly lower than those in the control group, and the index levels after treatment in the study group were lower than those before treatment(P<0.05). The number of pains and NRS scores in the study group was significantly lower than those in the control group(P<0.05), and the effective dose of the oxycodone hydrochloride release tablets was lower than that of the control group(P<0.05), and the incidence of adverse reactions in the study group was lower than that of the control group(P<0.05). Conclusion Rosuvastatin combined with oxycodone hydrochloride sustained-release tablets have a significant synergistic effect on cancer pain in patients with advanced non-small cell lung cancer, which can effectively reduce the incidence of adverse reactions.